Results
1 -
4 of
4Lucas Brian S., Fisher Benjamin, McGee Lawrence R., Olson Steven H., Medina Julio C., Cheung Eugene.
An Expeditious Synthesis of the MDM2–p53 Inhibitor AM-8553, Journal of the American Chemical Society, 2012 Sun Daqing, Li Zhihong, Rew Yosup, Gribble Michael, Bartberger Michael D., Beck Hilary P., Canon Jude, Chen Ada, Chen Xiaoqi, Chow David, Deignan Jeffrey, Duquette Jason, Eksterowicz John, Fisher Benjamin, Fox Brian M., Fu Jiasheng, Gonzalez Ana Z., Gonzalez-Lopez De Turiso Felix, Houze Jonathan B., Huang Xin, Jiang Min, Jin Lixia, Kayser Frank, Liu Jiwen (Jim), Lo Mei-Chu, Long Alexander M., Lucas Brian, McGee Lawrence R., McIntosh Joel, Mihalic Jeff, Oliner Jonathan D., Osgood Tao, Peterson Matthew L., Roveto Philip, Saiki Anne Y., Shaffer Paul, Toteva Maria, Wang Yingcai, Wang Yu Chung, Wortman Sarah, Yakowec Peter, Yan Xuelei, Ye Qiuping, Yu Dongyin, Yu Ming, Zhao Xiaoning, Zhou Jing, Zhu Jiang, Olson Steven H., Medina Julio C..
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development, Journal of Medicinal Chemistry, 2014 Niazi Sarfaraj, Purohit Madhusudan.
Rational design of promiscuous binding modulators of p53 inducing E3(Ub)-ligases (Mdm2 and Pirh2) as anticancer agents: an in silico approach, Med. Chem. Commun., 2015